MIRA Pharmaceuticals, Inc. (MIRA) - חוב לטווח ארוך להון

MIRA Pharmaceuticals (MIRA) capitalization depends on the success of clinical trials, ignoring macroeconomics. Revenues are planned through insurance payments for an opioid alternative for patients with chronic pain. The long-term debt-to-equity ratio on the general GURU.Markets platform chart, where the 0.00 mark shows the current state, confirms the analgesia synergy created through strategic alliances in the development of synthetic cannabinoids.

This ratio determines the proportion of long-term liabilities relative to equity, reflecting the company's degree of financial leverage. Analyzing this metric allows an investor to assess the stability of the financing structure, filtering out speculative price fluctuations. The current long-term debt-to-equity level visualizes the business's dependence on borrowed funds. For MIRA Pharmaceuticals (MIRA), this indicator is critical, as the company is currently in a cycle of clinical trials for analgesics. Under such conditions, low leverage minimizes bankruptcy risks until the drugs reach commercialization.